Barriers to Glaucoma Drug Delivery and Resolving the Challenges Using Nanotechnology

Fedorchak, Morgan V.

doi:10.1007/978-3-319-29346-2_17

Cited by 1 publication

(1 citation statement)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This represents a major drawback for lens-based drug delivery applications, as lenses would need to be changed at the appropriate intervals to ensure that therapeutic drug levels are being delivered. Moreover, inadequate handling and low compliance could lead to additional complications like contact lens-related dry eye and ocular surface infections (Fedorchak 2016;Dumbleton 2002;Dixon et al 2015;Hsu 2015;Ciolino et al 2014). This could be improved by using dissolvable lenses made of the natural protein collagen, which is the major component of the cornea and sclera.…”

Section: Contact Lensesmentioning

confidence: 99%

Nanomedicine and drug delivery to the retina: current status and implications for gene therapy

Tawfik

Chen

Goldberg

et al. 2022

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Blindness affects more than 60 million people worldwide. Retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, are the leading causes of blindness. Finding means to optimize local and sustained delivery of drugs or genes to the eye and retina is one goal to advance the development of new therapeutics. Despite the ease of accessibility of delivering drugs via the ocular surface, the delivery of drugs to the retina is still challenging due to anatomic and physiologic barriers. Designing a suitable delivery platform to overcome these barriers should enhance drug bioavailability and provide a safe, controlled, and sustained release. Current inventions for posterior segment treatments include intravitreal implants and subretinal viral gene delivery that satisfy these criteria. Several other novel drug delivery technologies, including nanoparticles, micelles, dendrimers, microneedles, liposomes, and nanowires, are now being widely studied for posterior segment drug delivery, and extensive research on gene delivery using siRNA, mRNA, or aptamers is also on the rise. This review discusses the current state of retinal drug/gene delivery and highlights future therapeutic opportunities.

show abstract